Skip to main content
main-content

01.12.2018 | Primary research | Ausgabe 1/2018 Open Access

Cancer Cell International 1/2018

MiR-384 inhibits the proliferation of colorectal cancer by targeting AKT3

Zeitschrift:
Cancer Cell International > Ausgabe 1/2018
Autoren:
Yong-Xia Wang, Hui-Fang Zhu, Zhe-Ying Zhang, Feng Ren, Yu-Han Hu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12935-018-0628-6) contains supplementary material, which is available to authorized users.

Abstract

Background

Growing evidence suggests that MiRNAs play essential roles in the initiation and progression of colorectal cancer (CRC). The aberrant expression of miR-384 has been reported in some cancers. However, the role and mechanism of miR-384 in CRC proliferation remains unknown.

Methods

The expression of miR-384 was detected in CRC and their paired normal tissues by real-time PCR. In vivo and in vitro assays were conducted to confirm the role of miR-384 in the proliferation of CRC. Bioinformatics analysis, luciferase reporter assays, western blot and in vitro assays were used to confirm that AKT3 was the target gene of miR-384. Finally, Spearman’s correlation analyses was carried out to analyze the relationship between miR-384 expression and AKT3 expression in CRC.

Results

MiR-384 was down‑regulated in CRC tissues. The in vivo and vitro functional assays verified that the ectopic upregulation of miR-384 inhibited the proliferation of CRC and the inhibition of miR-384 promoted the proliferation of CRC. Bioinformatics analysis, luciferase reporter assays, western blot and in vitro functional assays confirmed AKT3 as the target gene of miR-384. The expression of miR-384 was negatively correlated with the expressions of AKT3.

Conclusion

Our study verified that miR-384 could significantly suppress the proliferation of CRC by directing targeting AKT3.
Zusatzmaterial
Additional file 1. Additional table and figures.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Cancer Cell International 1/2018 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise